Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 360,316 shares of the company’s stock after buying an additional 18,093 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $6,039,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Ion Asset Management Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after acquiring an additional 2,383,500 shares during the period. Phoenix Financial Ltd. lifted its position in Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares during the period. Menora Mivtachim Holdings LTD. boosted its stake in Teva Pharmaceutical Industries by 2.8% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company’s stock valued at $448,640,000 after purchasing an additional 808,074 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock valued at $480,768,000 after purchasing an additional 2,350,000 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.86.

Teva Pharmaceutical Industries Stock Down 1.9%

Shares of Teva Pharmaceutical Industries stock opened at $24.01 on Monday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $25.00. The firm has a market capitalization of $27.53 billion, a PE ratio of -150.03, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The stock’s fifty day moving average is $19.74 and its 200-day moving average is $17.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $4.48 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.